This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under regulatory scrutiny.
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
146
146
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.
Bristol Myers Squibb (BMS) has been granted approval by the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.
Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.
Rebekah's father passed on his passion for science and problem solving to her and much her of childhood was spent doing fun hands-on activities from taking apart household mechanics to building rockets.
National Resilience’s subsidiary Resilience Government Services has received around $17.5m in funding for expanding critical medicine components manufacturing.
The push to increase diversity in clinical trials has gained momentum, but true progress requires more than regulatory mandates. It involves building trust, fostering authentic relationships and amplifying the voices of those most impacted by health inequities. While the pharmaceutical industry has made strides in improving patient diversity in clinical trials, a recent webinar moderated by Kevin Aniskovich, CEO of Jumo Health, underscored that much work remains to ensure trials are truly inclus
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).
The US Food and Drug Administration (FDA) has approved Exact Sciences’ Cologuard Plus, a next-generation, non-invasive colorectal cancer (CRC) screening test for adults aged 45 and older at average risk for CRC. Cologuard Plus builds on the original Cologuard test by incorporating enhanced biomarkers and laboratory processes, offering a more effective way to detect CRC at earlier, treatable stages and identify advanced precancers.
Today’s guest post comes from Timothy Nielsen, Vice President of Customer Success at AssistRx. Timothy discusses the affordability and patient journey challenges of specialty-lite products for patients, manufacturers, and health care providers. He explains how AssistRx's Advanced Access Anywhere (AAA) solution streamlines processes for specialty-lite products and facilitates enrollment via a digital hub.
Patient recruitment is a critical and often challenging aspect of clinical trials, particularly for biopharmaceutical companies seeking to accelerate drug development.
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo. In 2022, Enjaymo became the first and only therapy specifically approved by the FDA for treating patients with the uncommon blood disorder cold agglutinin disease.
The 16th annual PM360 Trailblazer Awards was a night to remember for EVERSANA INTOUCH! Our team was honored at Gotham Hall in New York City, taking home five awards across several categories: Gold: Marketing Team of the Year – Corcept Therapeutics Gold: Consumer Website/Online Initiative – Eczema Skin Gallery, Sanofi, Regeneron Pharmaceuticals, Inc.
Rheumatoid arthritis (RA) is the most common of the inflammatory arthropathies, affecting nearly 1% of the population with a female preponderance. Onset is typically between 45 and 65 years of age. While the etiology RA is unknown, it is thought to be largely autoimmune. Lack of treatment results in rapid progression of disease with significant joint destruction, pain, and loss of function.
In this episode, Ayesha spoke with James E. Brown, DVM, co-founder, President and CEO of DURECT. DURECT is pioneering a therapeutic strategy by leveraging the potential of epigenetic modulation to alter the trajectory of severe and life-threatening conditions like acute organ injury and cancer. The company is specifically focused on the development of an epigenetic modulator, larsucosterol (DUR-928) for the treatment of alcohol-associated hepatitis (AH).
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
October 6 is World Cerebral Palsy Day , an annual global event that helps raise awareness about cerebral palsy, and celebrate the lives and accomplishments of individuals living with the condition. Many will wear green to celebrate World Cerebral Palsy Day 2024. The theme of this year’s World Cerebral Palsy Day is “Uniquely CP,” which encourages individuals with the condition, their family members and supporters to share stories about their achievements and passions, highlighting how cerebral pa
Headlining our October issue of Pharmaceutical Commerce is a look inside an emerging key component of cold chain transport and management—ensuring the safety and control of novel injectable drugs through to their "last mile.
LSX 2024 features an insightful interview with Hakim Yadi and Luba Greenwood, discussing innovation, healthcare, and more. Learn from their expertise and perspectives in this exclusive discussion.
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content